Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2017035188) SYSTEMS AND METHODS FOR TREATING A DYSBIOSIS USING FECAL-DERIVED BACTERIAL POPULATIONS
Note: Text based on automatic Optical Character Recognition processes. Please use the PDF version for legal matters

Claims

What is claimed is:

1. A method, wherein the method treats a subject having a dysbiosis, the method comprising:

a. determining a first metabolic profile of the gut microbiome of a subject having a dysbiosis; and

b. changing the first metabolic profile of the gut microbiome of the subject to a second metabolic profile of the gut microbiome of the subject, by administering to the subject a composition comprising at least one bacterial strain selected from the group consisting of: Acidaminococcus intestinalis 14LG, Bacteriodes ovatus 5MM, Bifidobacterium adolescentis 20MRS, Bifidobacterium longum, Blautia sp. 27FM, Clostridium sp. 21FAA, Columella aerofaciens, Escherichia coli 3FM4i, Eubacterium desmolans 48FAA, Eubacterium eligens F1FAA, Eubacterium limosum 13LG, Faecalibacterum prausnitzii 40FAA, Lachnospira pectinoshiza 34FAA, Lactobacillus casei 25MRS, Parabacteroides distasonis 5FM, Roseburia faecalis 39FAA, Roseburia intestinalis 31FAA, Ruminococcus sp. 11FM, Ruminococcus species, and Ruminococcus torques 30FAA,

wherein the composition is administered at a therapeutically effective amount, sufficient to alter the first metabolic profile of the gut microbiome to the second metabolic profile of the gut microbiome,

wherein the first metabolic profile of the gut microbiome is a consequence of the dysbiosis, wherein the second metabolic profile of the gut microbiome treats the subject having the dysbiosis.

2. The method of claim 1, wherein the composition is administered at therapeutically effective amount, sufficient to colonize the gut of the subject.

3. The method of claim 1, wherein the composition comprises at least one bacterial strain selected from the group consisting of: 16-6-1 21 FAA 92% Clostridium cocleatum; 16-6-1 2 MRS 95% Blautia luti; 16-6-1 34 FAA 95% Lachnospira pectinoschiza; 32-6-1 30 D6 FAA 96% Clostridium glycyrrhizinilyticum: and 32-6-1 28 D6 FAA 94% Clostridium lactatifermentan .

4. The method of claim 1, wherein the dysbiosis is associated with gastrointestinal inflammation.

5. The method of claim 4, wherein the gastrointestinal inflammation is a result of at least one disease selected from the group consisting of: inflammatory bowel disease, irritable bowel syndrome, diverticular disease, ulcerative colitis, Crohn's disease, and indeterminate colitis.

6. The method of claim 1, wherein the dysbiosis is a Clostridium difficile infection.

7. The method of claim 1, wherein the dysbiosis is food poisoning.

8. The method of claim 1, wherein the dysbiosis chemotherapy-related dysbiosis.

9. A method, wherein the method treats a subject having a dysbiosis, the method comprising:

a. determining a first metabolic profile of the gut microbiome of a subject having a dysbiosis; and

b. changing the first metabolic profile of the gut microbiome of the subject to a second metabolic profile of the gut microbiome of the subject, by administering to the subject a composition comprising at least one bacterial species selected from the group consisting of: Acidaminococcus intestinalis, Bacteriodes ovatus, Bifidobacterium adolescentis, Bifidobacterium longum,

Blautia sp., Clostridium sp., Collinsella aerofaciens, Escherichia coli, Eubacterium desmolans, Eubacterium eligens, Eubacterium limosum, Faecalibacterum prausnitzii, Lachnospira pectinoshiza, Lactobacillus casei, Parabacteroides distasonis, Roseburia faecalis, Roseburia intestinalis, Ruminococcus sp., Ruminococcus species, and Ruminococcus torques,

wherein the composition is administered at a therapeutically effective amount, sufficient to alter the first metabolic profile of the gut microbiome to the second metabolic profile of the gut microbiome,

wherein the first metabolic profile of the gut microbiome is a consequence of the dysbiosis, wherein the second metabolic profile of the gut microbiome treats the subject having the dysbiosis.

10. The method of claim 9, wherein the composition is administered at therapeutically effective amount, sufficient to colonize the gut of the subject.

11. The method of claim 9, wherein the composition comprises at least one bacterial species selected from the group consisting of: Clostridium cocleatum; Blautia luti: Lachnospira pectinoschiza; Clostridium glycyrrhizinilyticum; and Clostridium lactatifermentans .

12. The method of claim 9, wherein the dysbiosis is associated with gastrointestinal inflammation.

13. The method of claim 12, wherein the gastrointestinal inflammation is a result of at least one disease selected from the group consisting of: inflammatory bowel disease, irritable bowel syndrome, diverticular disease, ulcerative colitis, Crohn's disease, and indeterminate colitis.

14. The method of claim 9, wherein the dysbiosis is a Clostridium difficile infection.

15. The method of claim 9, wherein the dysbiosis is food poisoning.

16. The method of claim 9, wherein the dysbiosis chemotherapy -related dysbiosis.